The global DNA diagnostics market size is expected to reach a value of USD 14.14 billion by 2030, growing at a CAGR of 4.14% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is due to advancements in genome sequencing and the development of personalized DNA-level diagnostic applications. In addition, the rising number of government-sponsored patented research initiatives and funded projects are anticipated to further drive demand in the market. For instance, in December 2022, the UK government announced a funding of USD 229.4 (£175) million for the development and creation of advanced genomic research.
The market growth is highly driven by the introduction of novel technologies for genome profiling. Moreover, with the increasing incidence of chronic oncology and infectious diseases that rely on DNA prototyping for treatment and diagnosis through personalized medicine, the demand for DNA diagnostics/testing-based research is anticipated to increase significantly over the forecast period. Furthermore, the increasing demand for DNA diagnostics/testing is driven by the rising demand for prenatal testing, and in-vitro fertilization is expected to provide positive growth prospects to the market. In September 2022, Eurofins Genoma announced the launch of niPGT-A, an embryo-free, non-invasive preimplantation screening test.
DNA diagnostics enables the comprehensive analysis of tumor genomes through techniques such as next-generation sequencing (NGS). NGS allows for the simultaneous sequencing of multiple genes, providing a detailed view of the genetic alterations present in the tumor. By comparing the tumor genome with normal tissue DNA, scientists and clinicians can identify specific mutations, copy number variations, and structural rearrangements unique to the cancer cells. In June 2022, Illumina, a DNA sequencing and array-based technology provider, introduces a research test developed in collaboration with Merck, aimed at unlocking deeper insights into the tumor genome.
Hepatitis C virus (HCV) is a global health concern, affecting millions of people worldwide. Accurate and timely diagnosis of HCV is crucial for effective treatment and prevention of further transmission. In this context, DNA diagnostics has emerged as a powerful tool for detecting and managing HCV infections. In July 2022, Roche introduced a groundbreaking dual antigen and antibody diagnostic test Elecsys HCV Duo, to aid the global efforts in eradicating the hepatitis C virus.
Request a free sample copy or view report summary: DNA Diagnostics Market Report
Based on technology, PCR-based diagnostics dominated the market in 2022 with a revenue share of 50.03% due to its extensive market usage and the wide availability of products
The NGS-based diagnosis segment is expected to grow at the fastest CAGR of 7.98% during the forecast period owing to the development of innovative and breakthrough advancements in the market. NGS platforms can process multiple samples in parallel, allowing for high-throughput sequencing
Based on application, the cancer genetics tests segment dominated the market in 2022 with a revenue share of 29.58% owing to the increase in disease outbreaks over the years
In terms of region, North America dominated the market in 2022 with a revenue share of 42.45%, which is attributed to several key factors, such as the presence of advanced healthcare infrastructure and robust government initiatives
Asia Pacific is expected to grow exponentially over the forecast period at the fastest CAGR of 6.23% owing to the growing R&D initiatives provided by governments in developing economies like China and India
Grand View Research has segmented the global DNA diagnostics market based on technology, application, and region:
DNA Diagnostics Technology Outlook (Revenue, USD Million, 2018 - 2030)
In-situ Hybridization Diagnostics
NGS DNA Diagnosis
DNA Diagnostics Application Outlook (Revenue, USD Million, 2018 - 2030)
Cancer Genetics Tests
Infectious Diseases DNA Testing
Newborn Genetic Screening
Preimplantation & Reproductive Diagnosis
Non-Infectious Diseases DNA Testing
CNS & PNS Related
Skeletal, Connective, Ectodermal & Dermal DNA Testing
Lung, Kidney, Liver & GT Related
Prenatal DNA Carrier Screening
Hematology & Immunology/Identity Diagnostics & Forensics
DNA Diagnostics Regional Outlook (Revenue, USD Million, 2018 - 2030)
Middle East & Africa
List of Key Players in the DNA Diagnostics Market
Beckman Coulter Inc.
Bio-Rad Laboratories, Inc.
Thermo Fisher Scientific Inc.
Siemens Healthcare GmbH
F. Hoffmann-La Roche
Agilent Technologies Inc.
GET A FREE SAMPLE
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
"The quality of research they have done for us has been excellent..."